Thus, attenuated RORC expression was correlated with a blunted tumor size- and IGF-1 reduction in patients treated with SA, indicating that these analogs may adversely affect clinical recovery in the presence of EMT progression (i.e., low E-cadherin) involving RORC-mediated mechanisms. Here, CDH1 is linked to neoplasm.